

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: A study of the Dutch SONABRE Registry

Marissa Meegdes, Sandra M.E. Geurts, Frans L.G. Erdkamp, M. Wouter Dercksen, Birgit E.P.J. Vriens, Kirsten N.A. Aaldering, Manon J.A.E. Pepels, Linda M.H. van de Winkel, Nathalie J.A. Teeuwen, Maaïke de Boer, Vivianne C.G. Tjan-Heijnen

Supplementary material

Figure S1. Cumulative rate of patients with ABC diagnosis from August 2017 that deceased without receiving CDK4/6 inhibitors

Figure S2. Cumulative rate of patients diagnosed with ABC between 2009 and August 2017 and alive on August 1st that deceased without receiving CDK4/6 inhibitors

Figure S1. Cumulative rate of patients with ABC diagnosis from August 2017 that deceased without receiving CDK4/6 inhibitors




Figure S2. Cumulative rate of patients diagnosed with ABC between 2009 and August 2017 and alive on August 1st that deceased without receiving CDK4/6 inhibitors

